Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19.

Taeyun KimDong-Hyun JooSeung Woo LeeJaejun Lee Sang Jin Lee Yun-Mi Song

Published in: Journal of clinical medicine (2022)

Regdanvimab usage was well tolerated and was associated with a decreased probability of requiring remdesivir, dexamethasone, and oxygen therapy. However, changes in SSS were not significantly different by the drug usage.

Keyphrases

coronavirus disease
sars cov
low dose
high dose
stem cells
adverse drug
respiratory syndrome coronavirus
drug induced